Loading
Total declarations
Companies
▲ Purchases (16 ops.)
▼ Sales (64 ops.)
Latest filing published 08 Dec 2025 for Salesforce, Inc., €21.5M.
Filing timeline
BuySaleG. Mason Morfit
Insider track record
Disclosed buys
16
Disclosed sells
64
Signal history
Closed purchases
Market purchases
16
Positive at T+90
100%
Median T+90
+8.2%
Based on 15 purchases whose 90-day window has closed (published at least 91 days ago), the same population our ranking model reads.
Purchases by company
Since each purchase
- +6.6%Entry US$28.65 · Close at T+90 US$30.54
- +13.1%Entry US$242.76 · Close at T+365 US$274.51
- +16.5%Entry US$42.41 · Close at T+365 US$49.41
- +21.1%Entry US$40.24 · Close at T+365 US$48.72
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
G. Mason Morfit: trading record in brief
G. Mason Morfit reported 29 sales worth EUR 3,043,455,163 in total, with a median of EUR 54,413,574. The three largest were made at Microsoft Corp: EUR 500,826,978 on July 28, 2016, EUR 321,474,319 on July 27, 2016 and EUR 317,306,121 on February 2, 2017. On the other side stand just 2 purchases, worth EUR 112,980,635: EUR 91,494,668 on June 3, 2024 and EUR 21,485,967 on December 5, 2025. Purchases are 6% of market trades.
The record holds 44 filings: 34 at Microsoft Corp (Director), 8 at Salesforce, Inc. (Director) and 2 at Valeant Pharmaceuticals International, Inc. (Director). It also contains 10 share grants and 3 option exercises.
The calendar is concentrated in 2016 and 2017, with 10 then 26 filings, before 3 in 2023, 4 in 2024 and 1 in 2025. Publication follows the trade by a median of 1 day. One filing falls in the last twelve months: the purchase of December 2025.
Morfit has 20, 12 and 10 own market trades within 30 days of colleagues at Microsoft Corp, in that order. Every one in the same direction. Names in order: William H. Gates III, Frank H. Brod and Amy Hood.
Companies and markets linked to G. Mason Morfit
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
Declarations124 total
96,000 shares@ US$260.586.1% of flowCommon StockSEC:0001418812-25-000036:0
Canonical exit: 5 Mar 2026 (T+90)
278,147 shares@ US$340.7220.4% of flowCommon StockSEC:0001418812-24-000026:1
15,353 shares@ US$340.551.1% of flowCommon StockSEC:0001418812-24-000026:2
722,300 shares@ US$346.1167.8% of flowCommon StockSEC:0001418812-24-000026:0
428,000 shares@ US$233.1726.1% of flowCommon StockSEC:0001418812-24-000014:0
Canonical exit: 1 Sept 2024 (T+90)
555 shares0Common StockSEC:0001418812-23-000076:0
554 shares0Common StockSEC:0001418812-23-000042:0
554 shares0Common StockSEC:0001418812-23-000031:0
589 shares0Common StockSEC:0001418812-17-000129:0
675 shares0Common StockSEC:0001418812-17-000085:0
3,157,400 shares@ US$72.617.1% of flowCommon StockSEC:0001418812-17-000061:0
342,600 shares@ US$72.610.8% of flowCommon StockSEC:0001418812-17-000061:1
2,879,500 shares@ US$72.506.5% of flowCommon StockSEC:0001418812-17-000061:2
312,331 shares@ US$72.500.7% of flowCommon StockSEC:0001418812-17-000061:3
278,000 shares@ US$72.500.6% of flowCommon StockSEC:0001418812-17-000061:4
30,169 shares@ US$72.500.1% of flowCommon StockSEC:0001418812-17-000061:5
710 shares0Common StockSEC:0001418812-17-000047:0
293,600 shares@ US$68.890.7% of flowCommon StockSEC:0001418812-17-000032:1
3,608,500 shares@ US$68.828.3% of flowCommon StockSEC:0001418812-17-000032:2
391,500 shares@ US$68.820.9% of flowCommon StockSEC:0001418812-17-000032:3
2,706,400 shares@ US$68.896.3% of flowCommon StockSEC:0001418812-17-000032:0
1,548,100 shares@ US$64.523.5% of flowCommon StockSEC:0001418812-17-000019:0
167,900 shares@ US$64.520.4% of flowCommon StockSEC:0001418812-17-000019:1
1,443,400 shares@ US$64.233.2% of flowCommon StockSEC:0001418812-17-000019:2
156,600 shares@ US$64.230.4% of flowCommon StockSEC:0001418812-17-000019:3
25 of 124 declarations
